Evidence map›Paper›PMID 32025740›Full record

ArticleInflammatory bowel diseases2021

Prevalence and Risk Factors of Substance Use Disorder in Inflammatory Bowel Disease.

Heather Carney, Ruth Ann Marrie, James M Bolton, Scott B Patten, Lesley A Graff, Charles N Bernstein, Kaarina Kowalec

Open access · hybridAbstract readEvaluation Study
In one paragraph

Article in Inflammatory bowel diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Lifestyle Factors and Silent Inflammatory Bowel Disease.Inflammatory intestinal diseases · 2023
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Polysubstance use in inflammatory bowel disease.Journal of digestive diseases · 2021
    Article
  13. Article
  14. Review
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Heather CarneyCollege of Pharmacy, Rady Faculty of Health Sciences, University of Manitoba, Manitoba, Canada.
Ruth Ann MarrieDepartment of Internal Medicine, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Manitoba, Canada.
James M BoltonDepartment of Community Health Sciences, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Manitoba, Canada.
Scott B PattenDepartment of Community Health Sciences, Cumming School of Medicine, University of Calgary, Alberta, Canada.
Lesley A GraffDepartment of Clinical Health Psychology, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Manitoba, Canada.
Charles N BernsteinDepartment of Internal Medicine, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Manitoba, Canada.
Kaarina KowalecCollege of Pharmacy, Rady Faculty of Health Sciences, University of Manitoba, Manitoba, Canada.
University of Manitoba · CAKarolinska Institutet · SEUniversity of Calgary · CA

Funding

CIHR THC-135234
6 · The paper itself

Abstract

backgroundSubstance use disorders (SUDs) impose a substantial individual and societal burden; however, the prevalence and associated factors in persons with inflammatory bowel disease (IBD) are largely unknown. We evaluated the prevalence and risk factors of SUD in an IBD cohort.

methodsInflammatory bowel disease participants (n = 247) were recruited via hospital- and community-based gastroenterology clinics, a population-based IBD research registry, and primary care providers as part of a larger cohort study of psychiatric comorbidity in immune-mediated inflammatory diseases. The Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders IV was administered to participants to identify lifetime SUD, anxiety disorder, and major depressive disorder. Additional questionnaires regarding participants' sociodemographic and clinical characteristics were also completed. We examined demographic and clinical factors associated with lifetime SUD using unadjusted and adjusted logistic regression modeling.

resultsForty-one (16.6%) IBD participants met the criteria for a lifetime diagnosis of an SUD. Factors associated with elevated odds of SUD were ever smoking (adjusted odds ratio [aOR], 2.96; 95% confidence interval [CI], 1.17-7.50), male sex (aOR, 2.44; 95% CI, 1.11-5.36), lifetime anxiety disorder (aOR, 2.41; 95% CI, 1.08-5.37), and higher pain impact (aOR, 1.08; 95% CI, 1.01-1.16).

conclusionsOne in six persons with IBD experienced an SUD, suggesting that clinicians should maintain high index of suspicion regarding possible SUD, and inquiries about substance use should be a part of care for IBD patients, particularly for men, smokers, and patients with anxiety disorders and pain.

Indexed as

AdultAnxiety DisordersColitis, UlcerativeCrohn DiseaseFemaleHumansInflammatory Bowel DiseasesMajor Depressive DisorderMaleMiddle AgedPrevalenceRisk FactorsSubstance-Related DisordersSurveys and Questionnairesinflammatory bowel diseaseSCIDsubstance use disorders

Identifiers

PMID32025740
PMCPMC7737154
OpenAlexW3004674462

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.